TY  - GEN
AU  - Willett,Christopher G
AU  - Boucher,Yves
AU  - Duda,Dan G
AU  - di Tomaso,Emmanuelle
AU  - Munn,Lance L
AU  - Tong,Ricky T
AU  - Kozin,Sergey V
AU  - Petit,Lucine
AU  - Jain,Rakesh K
AU  - Chung,Daniel C
AU  - Sahani,Dushyant V
AU  - Kalva,Sanjeeva P
AU  - Cohen,Kenneth S
AU  - Scadden,David T
AU  - Fischman,Alan J
AU  - Clark,Jeffrey W
AU  - Ryan,David P
AU  - Zhu,Andrew X
AU  - Blaszkowsky,Lawrence S
AU  - Shellito,Paul C
AU  - Mino-Kenudson,Mari
AU  - Lauwers,Gregory Y
TI  - Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
SN  - 0732-183X
PY  - 2005///1209
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bevacizumab
KW  - Biomarkers
KW  - Combined Modality Therapy
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neovascularization, Pathologic
KW  - prevention & control
KW  - Prognosis
KW  - Radiotherapy Dosage
KW  - Rectal Neoplasms
KW  - blood supply
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase I; Letter
UR  - https://doi.org/10.1200/JCO.2005.02.5635
ER  -